Korean J Gastroenterol.  2024 Jan;83(1):1-5. 10.4166/kjg.2023.135.

Microbiome and Biliary Tract Cancer

• Park JS

• KMID: 2552236
• DOI: http://doi.org/10.4166/kjg.2023.135

Abstract

Biliary tract cancers encompass a group of malignancies that affect the bile ducts and gallbladder and are associated with a poor prognosis, often due to late diagnosis and limited treatment options. The incidence of biliary tract cancer has been increasing gradually, underscoring the need for a better understanding of its pathogenesis and potential risk factors. Research suggests that biliary tract cancer may develop through a combination of genetic and epigenetic alterations, as well as environmental factors. The role of microbial exposure and the human microbiome in the pathogenesis of biliary tract cancer is an emerging area of interest. Traditionally, the biliary tree was considered sterile under normal conditions, but recent studies have identified associations between specific microbiological patterns and inflammatory biliary diseases and cancer. The human microbiome plays a crucial role in maintaining host homeostasis and interacting with the host's immune system. Dysbiosis, or an imbalance in the microbiome composition, has been implicated in the development of various diseases, including cancer. Hence, dysbiosis in the biliary tract might trigger the pathogenesis of biliary tract cancer. Advances in next-generation sequencing technology have provided researchers with a more comprehensive view of the microbiota and their potential roles in health and disease, providing more evidence of the relationship between the microbiota and biliary tract cancer. This review summarizes the latest evidence of the microbiome that would be associated with biliary tract cancer.

Keyword

Microbiome; Gallbladder cancer; Cholangiocarcinoma

Reference

1. Nakeeb A, Pitt HA, Sohn TA, et al. 1996; Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 224:463–473. discussion 473–475. DOI: 10.1097/00000658-199610000-00005. PMID: 8857851. PMCID: PMC1235406.

2. Valle J, Wasan H, Palmer DH, et al. 2010; Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. DOI: 10.1056/NEJMoa0908721. PMID: 20375404.

3. Hsing AW, Bai Y, Andreotti G, et al. 2007; Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int J Cancer. 121:832–838. DOI: 10.1002/ijc.22756. PMID: 17450525. PMCID: PMC2885776.

4. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. 2020; Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol. 72:95–103. DOI: 10.1016/j.jhep.2019.09.007. PMID: 31536748.

5. Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. 2014; Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 21:301–308. DOI: 10.1002/jhbp.62. PMID: 24408775.

6. Sender R, Fuchs S, Milo R. 2016; Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14:e1002533. DOI: 10.1371/journal.pbio.1002533. PMID: 27541692. PMCID: PMC4991899.

7. Gao R, Wang Z, Li H, et al. 2020; Gut microbiota dysbiosis signature is associated with the colorectal carcinogenesis sequence and improves the diagnosis of colorectal lesions. J Gastroenterol Hepatol. 35:2109–2121. DOI: 10.1111/jgh.15077. PMID: 32337748.

8. Tripathi A, Debelius J, Brenner DA, et al. 2018; The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 15:397–411. DOI: 10.1038/s41575-018-0011-z. PMID: 29748586. PMCID: PMC6319369.

9. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. 2013; Pleiotropic roles of bile acids in metabolism. Cell Metab. 17:657–669. DOI: 10.1016/j.cmet.2013.03.013. PMID: 23602448. PMCID: PMC3654004.

10. Scheufele F, Schorn S, Demir IE, et al. 2017; Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. Surgery. 161:939–950. DOI: 10.1016/j.surg.2016.11.001. PMID: 28043693.

11. Shrader HR, Miller AM, Tomanek-Chalkley A, et al. 2021; Effect of bacterial contamination in bile on pancreatic cancer cell survival. Surgery. 169:617–622. DOI: 10.1016/j.surg.2020.09.029. PMID: 33268071. PMCID: PMC7870517.

12. Nath G, Gulati AK, Shukla VK. 2010; Role of bacteria in carcinogenesis, with special reference to carcinoma of the gallbladder. World J Gastroenterol. 16:5395–5404. DOI: 10.3748/wjg.v16.i43.5395. PMID: 21086555. PMCID: PMC2988230.

13. Karin M, Greten FR. 2005; NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 5:749–759. DOI: 10.1038/nri1703. PMID: 16175180.

14. Caygill CP, Hill MJ, Braddick M, Sharp JC. 1994; Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet. 343:83–84. DOI: 10.1016/S0140-6736(94)90816-8. PMID: 7903779.

15. Haghjoo E, Galán JE. 2004; Salmonella typhi encodes a functional cytolethal distending toxin that is delivered into host cells by a bacterial-internalization pathway. Proc Natl Acad Sci U S A. 101:4614–4619. DOI: 10.1073/pnas.0400932101. PMID: 15070766. PMCID: PMC384795.

16. Nath G, Singh YK, Kumar K, et al. 2008; Association of carcinoma of the gallbladder with typhoid carriage in a typhoid endemic area using nested PCR. J Infect Dev Ctries. 2:302–307. DOI: 10.3855/jidc.226. PMID: 19741293.

17. Nagaraja V, Eslick GD. 2014; Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther. 39:745–750. DOI: 10.1111/apt.12655. PMID: 24612190.

18. Koshiol J, Wozniak A, Cook P, et al. 2016; Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and metaanalysis. Cancer Med. 5:3310–3235. DOI: 10.1002/cam4.915. PMID: 27726295. PMCID: PMC5119987.

19. Zhou D, Wang JD, Weng MZ, et al. 2013; Infections of Helicobacter spp. in the biliary system are associated with biliary tract cancer: a meta-analysis. Eur J Gastroenterol Hepatol. 25:447–454. DOI: 10.1097/MEG.0b013e32835c0362. PMID: 23470268.

20. Avilés-Jiménez F, Guitron A, Segura-López F, et al. 2016; Microbiota studies in the bile duct strongly suggest a role for Helicobacter pylori in extrahepatic cholangiocarcinoma. Clin Microbiol Infect. 22:178.e11–178.e22. DOI: 10.1016/j.cmi.2015.10.008. PMID: 26493848.

21. Segura-López FK, Avilés-Jiménez F, Güitrón-Cantú A, et al. 2015; Infection with Helicobacter bilis but not Helicobacter hepaticus was associated with extrahepatic cholangiocarcinoma. Helicobacter. 20:223–230. DOI: 10.1111/hel.12195. PMID: 25582431.

22. Murphy G, Michel A, Taylor PR, et al. 2014; Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study. Hepatology. 60:1963–1971. DOI: 10.1002/hep.27193. PMID: 24797247. PMCID: PMC4216769.

23. Serra N, Di Carlo P, Gulotta G, et al. 2018; Bactibilia in women affected with diseases of the biliary tract and pancreas. A STROBE guidelines-adherent cross-sectional study in Southern Italy. J Med Microbiol. 67:1090–1095. DOI: 10.1099/jmm.0.000787. PMID: 29975626.

24. Cococcioni L, Panelli S, Varotto-Boccazzi I, et al. 2021; IBDs and the pediatric age: Their peculiarities and the involvement of the microbiota. Dig Liver Dis. 53:17–25. DOI: 10.1016/j.dld.2020.10.033. PMID: 33189590.

25. Poudel SK, Padmanabhan R, Dave H, et al. 2023; Microbiomic profiles of bile in patients with benign and malignant pancreaticobiliary disease. PLoS One. 18:e0283021. DOI: 10.1371/journal.pone.0283021. PMID: 37071646. PMCID: PMC10112786.

26. Zhang L, Wu YN, Chen T, Ren CH, Li X, Liu GX. 2019; Relationship between intestinal microbial dysbiosis and primary liver cancer. Hepatobiliary Pancreat Dis Int. 18:149–157. DOI: 10.1016/j.hbpd.2019.01.002. PMID: 30661942.

27. Zhang Q, Ma C, Duan Y, et al. 2021; Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discov. 11:1248–1267. DOI: 10.1158/2159-8290.CD-20-0304. PMID: 33323397. PMCID: PMC8102309.

28. Mao J, Wang D, Long J, et al. 2021; Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 9:e003334. DOI: 10.1136/jitc-2021-003334. PMID: 34873013. PMCID: PMC8650503.